Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.72 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.72 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.72 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.72 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.72 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72073 | 0.99 | CHRM3 (0.74) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL19372404 | 0.88 | CHRM3 (0.74) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL10746468 | 0.87 | CHRM3 (0.76) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17313099 | 0.86 | CHRM3 (0.70) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17313101 | 0.86 | CHRM3 (0.70) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Quinuclidinyl Benzilate SCHEMBL29433215 | 0.85 | CHRM2 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Quinuclidinyl Benzilate SCHEMBL241173 | 0.84 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Quinuclidinyl Benzilate SCHEMBL59698 | 0.84 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3306597 | 0.82 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2127514 | 0.82 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119789854-A | Compositions and methods for delivering ophthalmic actives | ADS医疗有限责任公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025034554-A9 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-03-13 | — | — | WO | claimed |
| WO-2025034554-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-02-13 | — | — | WO | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-118964912-B | Method and device for evaluating neural network load prediction result based on SHAP value | 国网江苏省电力有限公司镇江供电分公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119789854-A | Compositions and methods for delivering ophthalmic actives | ADS医疗有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025034554-A9 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025034554-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-02-13 | — | — | WO | disclosed |
| CN-114126645-A | Modified S1 subunit of coronavirus spike protein | 勃林格殷格翰动物保健有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-9707220-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | The Governmen of the United States of America, as represented by Secretary, Department of Health and (US) | 2014-12-25 | — | — | US | disclosed |
| US-8859585-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-14 | — | — | US | disclosed |
| EP-1896025-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-11-30 | — | — | US | disclosed |
| WO-2006127418-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | CHRNA1, SLC18A3, CHRNB1 | CHRM3 7/4885CHRM2 10/4885CHRM1 4/4885 |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | CHRNA1, CHRNA2, SLC18A3 | CHRM3 11/4885CHRM2 9/4885CHRM1 5/4885 |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | CHRM5, CHRM3, CHRM2 | CHRM3 2/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.